Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTX-SBRT in Borderline Resectable Pancreatic Cancer
NCT01754623Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Feb 2013
- Primary completion
- Sep 2014
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, docetaxel, capecitabine in pancreatic cancer (PC), sponsored by Moffitt Cancer Center. Started Feb 2013; status: terminated.
02
Drugs
gemcitabinedocetaxelcapecitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01754623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01754623.